Crowley Wealth Management Inc. Takes $2.57 Million Position in Stryker Co. (NYSE:SYK)

Crowley Wealth Management Inc. acquired a new position in Stryker Co. (NYSE:SYK) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,126 shares of the medical technology company’s stock, valued at approximately $2,566,000. Stryker makes up 2.3% of Crowley Wealth Management Inc.’s holdings, making the stock its 14th largest holding.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker during the 4th quarter valued at about $25,000. Dunhill Financial LLC raised its stake in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Rakuten Securities Inc. lifted its position in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in Stryker in the 4th quarter worth approximately $30,000. Finally, BankPlus Trust Department bought a new position in shares of Stryker in the 4th quarter worth $33,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $371.38 on Friday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The firm has a market capitalization of $141.71 billion, a P/E ratio of 47.86, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $384.28 and a two-hundred day simple moving average of $374.03.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company earned $3.46 EPS. On average, equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research report on Friday. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Canaccord Genuity Group lifted their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.